Completed Iron Overload trials: Trial Insights

Filters: Condition: Iron Overload Status: Completed Clear all

101 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2000	2
2001	1
2002	2
2003	7
2004	2
2005	5
2006	3
2007	10
2008	11
2009	7
2010	5
2011	6
2012	4
2013	6
2014	4
2015	3
2016	2
2018	3
2019	5
2020	3
2022	3
2024	3

Trials by status
Category	Trials
Completed	101

Top lead sponsors
Category	Trials
Novartis Pharmaceuticals	30
Rennes University Hospital	6
ApoPharma	4
HaEmek Medical Center, Israel	4
St. Jude Children's Research Hospital	3
University of Wisconsin, Madison	3
Children's Hospital Los Angeles	2
Hangzhou Zede Pharma-Tech Co., Ltd.	2
Lipomed	2
National Heart, Lung, and Blood Institute (NHLBI)	2

Top conditions
Category	Trials
Iron Overload	101
Thalassemia	30
beta-Thalassemia	22
Hemochromatosis	14
Anemia, Sickle Cell	13
Myelodysplastic Syndromes	11
Hemosiderosis	7
Anemia	6
Hematologic Diseases	4
Anemia, Aplastic	3

Trials

Showing 76 to 100 of 101. Each trial links to its page on Pharma Observatory.

Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging NCT00401336Not applicableCompletedRennes University HospitalStarted 2006
Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis NCT00395629Phase 1/2CompletedNovartis PharmaceuticalsStarted 2006
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment NCT00447694Phase 2CompletedNovartisStarted 2006
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients NCT00117507Phase 4CompletedNovartis PharmaceuticalsStarted 2005
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients NCT00110266Phase 2CompletedNovartis PharmaceuticalsStarted 2005
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) NCT00171301Phase 4CompletedNovartis PharmaceuticalsStarted 2005
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients NCT00110617Phase 2CompletedNovartis PharmaceuticalsStarted 2005
Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients NCT00349453Phase 2CompletedLipomedStarted 2005
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload NCT00171210Phase 3CompletedNovartis PharmaceuticalsStarted 2004
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients NCT00303329Phase 2CompletedNovartis PharmaceuticalsStarted 2004
Cytochrome P450 2E1 and Iron Overload NCT00138684Phase 2CompletedRennes University HospitalStarted 2003
A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload. NCT00390858Phase 2CompletedNovartis PharmaceuticalsStarted 2003
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions NCT00061750Phase 3CompletedNovartis PharmaceuticalsStarted 2003
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias NCT00061763Phase 2CompletedNovartis PharmaceuticalsStarted 2003
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions NCT00067080Phase 2CompletedNovartis PharmaceuticalsStarted 2003
Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy NCT01874405ObservationalCompletedUniversity of Campania Luigi VanvitelliStarted 2003
Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study NCT01033747Phase 2/3CompletedNovartis PharmaceuticalsStarted 2003
Efficacy Study in Removing Excess Iron From the Heart NCT00105495Phase 4CompletedApoPharmaStarted 2002
Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients NCT00350662Phase 3CompletedLipomedStarted 2002
Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major NCT00800761Phase 4CompletedOspedale MicrocitemicoStarted 2001
Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) NCT00000623ObservationalCompletedCarelon ResearchStarted 2000
Hemochromatosis and Iron Overload Screening Study (HEIRS) NCT00005541ObservationalCompletedNational Heart, Lung, and Blood Institute (NHLBI)Started 2000
Combination Iron Chelation Therapy NCT00004982Phase 1CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Started 1998
Iron Overload in African Americans NCT00001455ObservationalCompletedEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Started 1995
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone NCT00000588Phase 2CompletedCase Western Reserve UniversityStarted 1989

1 more trial matches. See them on Pharma Observatory

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory